Antibacterial and Anti-Inflammatory Activity of an Antimicrobial Peptide Synthesized with D Amino Acids

Area of Science:

• Microbiology
• Pharmacology
• Immunology

Background:

• The tetra-branched peptide SET-M33 is under development as an antibiotic against Gram-negative bacteria.
• An isomeric form, SET-M33D, utilizing D-amino acids, demonstrates efficacy against Gram-positive bacteria due to enhanced protease resistance.

Purpose of the Study:

• To evaluate the in vitro and in vivo antibacterial activity of SET-M33D.
• To assess the anti-inflammatory properties of SET-M33D by examining its effects on key inflammatory mediators.
• To determine the potential of SET-M33D as a broad-spectrum antibiotic candidate.

Main Methods:

• In vitro antimicrobial susceptibility testing (MIC) against various Gram-positive and Gram-negative pathogens.
• In vivo efficacy studies using a mouse model challenged with Methicillin-resistant Staphylococcus aureus (MRSA).
• Assessment of anti-inflammatory effects through neutralization assays for lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and measurement of inflammatory marker expression.

Main Results:

• SET-M33D exhibited strong in vitro activity against multiresistant pathogens, including Staphylococcus aureus, Staphylococcus saprophyticus, Enterococcus faecalis, and enterobacteriaceae (MIC range 0.7-6.0 µM).
• In vivo studies confirmed SET-M33D's efficacy against MRSA at clinically relevant doses (5 and 2.5 mg/Kg).
• SET-M33D effectively neutralized LPS and LTA, significantly reducing the expression of pro-inflammatory cytokines, enzymes, and transcription factors (e.g., TNF-α, IL6, COX-2, NF-κB).

Conclusions:

• SET-M33D displays potent broad-spectrum antibacterial activity against clinically relevant resistant pathogens.
• The peptide possesses significant anti-inflammatory properties through the neutralization of bacterial endotoxins.
• Favorable toxicity profiles and low resistance selection frequency position SET-M33D as a strong candidate for developing a novel, broad-spectrum antibiotic.